Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12122
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZargar, Homayounen
dc.contributor.authorAning, Jonathanen
dc.contributor.authorIschia, Joseph Jen
dc.contributor.authorSo, Alanen
dc.contributor.authorBlack, Peteren
dc.date.accessioned2015-05-16T01:46:17Z
dc.date.available2015-05-16T01:46:17Z
dc.date.issued2014-03-11en
dc.identifier.citationNature Reviews. Urology 2014; 11(4): 220-30en
dc.identifier.govdoc24619373en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12122en
dc.description.abstractNearly three-quarters of all newly diagnosed urothelial cancers are non-muscle-invasive bladder cancers (NMIBCs). Although bladder-preserving surgery can be used to treat NMIBC, the rate of recurrence remains high. Intravesical chemotherapy has been shown to reduce the rate of NMIBC recurrence, and mitomycin C (MMC) has become the most commonly used intravesical cytotoxic agent. Despite the popularity of this agent in the treatment of NMIBCs, many questions regarding the optimal approach to MMC therapy remain unanswered. Strategies to enhance delivery of MMC have been well studied and multiple measures are recommended for implementation in routine clinical practice. In addition, less widely investigated techniques, such as hyperthermia and electromotive drug administration, have been shown to increase the efficacy of MMC therapy. Nevertheless, even when the current 'optimal' approaches to MMC administration are used, a large proportion of NMIBCs recur. This apparent treatment resistance might be overcome by combination of MMC with other agents that have different mechanisms of action and are unlikely to have cross-resistance. Study of the mechanisms of resistance is, therefore, important to identify key pathways underlying this phenomenon, which could be rationally targeted using specific combinations of drugs. Knowledge of these mechanisms might also reveal markers of responsiveness to therapy that could be used for patient selection.en
dc.language.isoenen
dc.subject.otherAdministration, Intravesicalen
dc.subject.otherAntibiotics, Antineoplastic.administration & dosageen
dc.subject.otherDrug Resistance, Neoplasmen
dc.subject.otherDrug Therapy, Combinationen
dc.subject.otherHumansen
dc.subject.otherMitomycin.administration & dosageen
dc.subject.otherNeoplasm Invasivenessen
dc.subject.otherUrinary Bladder Neoplasms.drug therapy.pathologyen
dc.titleOptimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleNature reviews. Urologyen
dc.identifier.affiliationDepartment of Urology, Center for Robotic and Laparoscopic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.en
dc.identifier.affiliationDepartment of Urology, Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, UK.en
dc.identifier.affiliationDepartments of Surgery and Urology, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC 3084, Australia.en
dc.identifier.affiliationDepartment of Urological Sciences, Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.en
dc.identifier.doi10.1038/nrurol.2014.52en
dc.description.pages220-30en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/24619373en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.